Table 8.
Potential drug candidates of mRNAs in the ceRNA networks in SCLC.
| mRNAs | Drug candidate | Type* | Therapy* | Main roles* | Data resource |
|---|---|---|---|---|---|
| Colony-stimulating factor 3 receptor (CSF3R) | FavId | an active immunotherapy | Tumour therapy | based upon unique genetic information extracted from a patient’s tumour | https://go.drugbank.com/drugs/DB05249 |
| Pegfilgrastim | a recombinant human granulocyte colony stimulating factor | Adjuvant therapy | stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy | https://go.drugbank.com/drugs/DB00019 | |
| Filgrastim | a form of recombinant human granulocyte colony stimulating factor | Adjuvant therapy | induce the production of granulocytes and lower infection risk after myelosuppressive therapy | https://go.drugbank.com/drugs/DB00099 | |
| Lenograstim | a granulocyte colony-stimulating factor | Adjuvant therapy | reduce the duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors | https://go.drugbank.com/drugs/DB13144 | |
| Lipegfilgrastim | a medication | Adjuvant therapy | reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy | https://go.drugbank.com/drugs/DB13200 | |
| Acid alpha-glucosidase (GAA) | Trastuzumab deruxtecan | an antibody | Tumour therapy | treat certain types of unresectable or metastatic HER-2 positive breast cancer | https://go.drugbank.com/drugs/DB14962 |
| Acarbose | an alpha-glucosidase inhibitor | Other therapy | adjunctly with diet and exercise for the management of glycaemic control in patients with type 2 diabetes mellitus. | https://go.drugbank.com/drugs/DB00284 | |
| AT2220 | pharmacological chaperones | Other therapy | increase GAA activity in cell lines derived from Pompe patients a n d in transfected cells expressing misfolded forms of GAA | https://go.drugbank.com/drugs/DB05200 | |
| Miglitol | an oral alpha-glucosidase inhibitor | Other therapy | improve glycaemic control by delaying the digestion of carbohydrates | https://go.drugbank.com/drugs/DB00491 | |
| FGR Proto-Oncogene, Src Family Tyrosine Kinase (FGR) | Dasatinib | a tyrosine kinase inhibito | Tumour therapy | treat lymphoblastic or chronic myeloid leukaemia with resistance or intolerance to prior therapy | https://go.drugbank.com/drugs/DB01254 |
| Zanubrutinib | a kinase inhibitor | Tumour therapy | treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. | https://go.drugbank.com/drugs/DB015035 | |
| Fostamatinib | a spleen tyrosine kinase inhibitor | Other therapy | treat chronic immune thrombocytopenia after attempting one other treatment. | https://go.drugbank.com/drugs/DB12010 |
ceRNA, competing endogenous RNA; SCLC, small cell lung cancer; HER-2, human epidermal growth factor receptor-2; *, the information is from Drugbank (https://go.drugbank.com/).